Follow us on Bluesky
Bluesky · Hashtag

#Regn

49
posts · 30d
5
users
2
posts / day
9.8
posts / user
+ 40% vs last week

#Regn is an active hashtag on Bluesky. In the last 30 days, 5 people shared 49 posts with it — around 2 a day. Activity is up 40% versus the previous week, peaking on Sep 3 with 6 posts.

#Regn posts per day (last 30 days)

Related tags

Tags most often used together with #Regn.

#Nyheder 42 #DKMedier 42

Posts with #Regn

Bertha Coombs
@berthacoombs.cnbc.com
over 1 year ago
Maintaining muscle mass would be especially helpful for elderly patients at risk of falls. If the drug wins approval and #REGN combo becomes standard of care, it might provide a boost to Novo's Wegovy just when Medicare would initiate negotiated prices on its GLP-1s in 2027.

in mid-stage trial Regeneron's weight-loss drug combined with Wegovy preserved lean muscle mass. The clinical name-- wait for it-- Trevogrumab. Who comes up with these names?!!
0 0 3
The Nordic Ticker - Paywall-free Headlines
@nordic.skyen.live
5 days ago
🇩🇰 Nordjylland venter grå og våd torsdag #NordicNews #Nyheder #Nordjylland #Regn #Torsdag #DKMedier
Grå og våd torsdag i vente

www.tv2nord.dk

Grå og våd torsdag i vente

Det kan være klogt at huske paraplyen i dag. For en grå og våd torsdag venter Nordjylland. Morgenen starter med lidt sol mellem skyerne, men allerede om formiddagen trækker regn ind fra vest og breder sig mod øst gennem dagen. Temperaturen ligger omkring 15 grader, og der falder typisk 5 mm regn, men nogle steder ...
0 0 0
StockTitan
@stocktitan.net
about 1 year ago
#REGN Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma www.stocktitan.net/news/R…
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

www.stocktitan.net

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Regeneron Pharmaceuticals (NASDAQ: REGN) has received FDA accelerated approval for Lynozyfic™ (linvoseltamab-gcpt), the first BCMAxCD3 bispecific antibody for treating relapsed or refractory multiple myeloma in adults who have received at least four prior therapies.The approval is based on the LINKER-MM1 trial results, where patients (n=80) achieved a 70% objective response rate, with 45% reaching complete response or better. The median duration of response was not reached, with an estimated 89% duration of response at 9 months.Lynozyfic features a unique dosing schedule, allowing administration every two weeks starting at week 14, and potentially every four weeks with good response. The treatment includes mandatory hospitalization during initial dosing for safety monitoring.
0 0 2

Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.

View all posts on Bluesky

Explore trending tags

#art #oc #nsfw #furry #digitalart #fanart #furryart #AI #photography #gay #illustration #fcf
Back to all tags